On September 15, 2026, XPENG-W (09868.HK) traded weaker in the afternoon. As of 14:45, the stock was quoted at HK$40.40, down 3.86%.
on 15 September 2026, AI chip stocks traded with volatility while ASMPT (00522.HK) strengthened. As of 14:19, the company quoted HKD 154.400, up 0.06%.
on 15 September 2026, humanoid robot stocks traded with volatility while MIDEA GROUP (00300.HK) strengthened. As of 13:47, the company quoted HKD 100.400, up 0.40%.
On 15 September 2026, GENFLEET-B (02595.HK) announced that updated Phase II data of GFH375 monotherapy in previously treated KRAS G12D-mutant NSCLC were presented at the 2026 World Conference on Lung Cancer, with a confirmed objective response rate of 52.1%.
On 15 September 2026, UNISOUND (09678.HK) announced the launch of U2-Flash, a new-generation high-density intelligent model whose DeepSWE v1.1 score doubled from the previous generation to 64.6.
On 15 September 2026, BIOHEART-B (02185.HK) announced that it recently entered into a strategic cooperation agreement with Shanghai Shenqi Medical Technology Co., Ltd. to jointly advance the commercialisation and clinical application of the BioHeart bioresorbable rapamycin-eluting coronary stent system. The agreement is a framework agreement and is non-binding, and as of the date of the announcement the two parties had not entered into a formal or legally binding agreement, so the cooperation may or may not materialise.
On 14 September 2026, BOAN BIOTECH (06955.HK) announced that the investigational new drug application for its PD-1/IL-2 antibody-cytokine prodrug BA1203 has been approved by the Centre for Drug Evaluation of the National Medical Products Administration of the PRC, with the drug intended for the treatment of multiple solid tumours.
On 14 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. received a Notice of Acceptance from the National Medical Products Administration, with the marketing application for SHR-2004 injection, a Class 1 innovative drug and coagulation factor XI monoclonal antibody, accepted for the proposed indication of preventing venous thromboembolism in adult patients undergoing elective knee replacement surgery, under acceptance number CXSS2600151.
On 14 September 2026, CMS (00867.HK) announced that CMS-D001 tablets, an innovative drug, obtained a drug clinical trial approval notice issued by the National Medical Products Administration on 11 September 2026 and received by the Company on 14 September, with the NMPA agreeing to clinical trials evaluating the efficacy and safety of the drug in treating the systemic lupus erythematosus indication.
On September 14, 2026, the three major Hong Kong stock indices moved mixed, with the Hang Seng Index up 0.45%, the Hang Seng TECH Index down slightly by 0.06%, and the Hang Seng China Enterprises Index up 0.46%. AI concept stocks came under broad pressure on the day, with the LLM sector under broad pressure, AI Chips mixed, and the Autonomous Driving sector mostly declining.
On 14 September 2026, LEADS BIOLABS-B (09887.HK) announced that the Company presented updated Phase II clinical study data for Vilxin® (Opatilimab, PD-L1/4-1BB bispecific antibody) in combination with chemotherapy as first-line treatment for NSCLC in an oral presentation at WCLC 2026; as at 1 July 2026, among 62 efficacy-evaluable patients, the ORR in the overall patient population reached 71.0%, the DCR reached 95.2% and the 6-month PFS rate reached 70.6%.
On September 14, 2026, BIDU-W (09888.HK) edged higher in intraday trading. As of 14:34, the stock quoted HK$89.60, up 0.56%.
on 14 September 2026, AI chip stocks traded with volatility while HUA HONG GRACE (01347.HK) weakened. As of 13:58, the company quoted HKD 107.200, down 4.03%.
on 14 September 2026, humanoid robot stocks traded with volatility while XIAOMI-W (01810.HK) strengthened. As of 13:24, the company quoted HKD 27.020, up 2.50%.
On 13 September 2026, Shenzhen Hai Robotics Innovation Group Co., Ltd. published an application proof on the website of the Stock Exchange seeking the listing of its H shares on the Main Board, with Goldman Sachs (Asia) L.L.C. and CITIC Securities (Hong Kong) Limited as joint sponsors; the filing shows 2025 revenue of RMB 2,016.9 million and a gross margin of 31.2%, with the Company ranked as the world's largest ACR solution provider by 2025 revenue and shipment volume with a market share of over 30%, and revenue of RMB 1,118.1 million in the first half of 2026. The application proof is a draft, and the offer price and the number of offer shares remain to be determined.
On 14 September 2026, 160 HEALTH (02656.HK) announced in a voluntary announcement that its domestic subsidiary had completed the delivery of an integrated solution in a total amount of RMB 12.2 million to a big health enterprise focusing on the research and development of smart wearable health devices, and had obtained an acceptance certificate, with the solution comprising a smart health monitoring system, computing power infrastructure and integrated commissioning services; the announcement cautioned that the business remains at an early stage and has not yet formed a scaled or recurring revenue model, and that the order is not a discloseable transaction under Chapter 14 or a connected transaction under Chapter 14A of the Listing Rules.
